1921
Volume 101, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Medication adherence is critical to the effectiveness of benznidazole (BZ) therapy for the treatment of Chagas disease. Assessing BZ adherence using traditional plasma sampling methods presents numerous challenges in resource-limited settings. Dried blood spot (DBS) sampling of BZ can be used to overcome logistical barriers and provides a less invasive method for assessing BZ levels. A BZ DBS assay using liquid chromatography-tandem mass spectrometry was developed and applied to a clinical study of infants and children being treated with BZ for infection in Argentina. The assay was validated over a concentration range of 9.8–5,000 ng/mL. Inter-assay and intra-assay measures ranged from −2.9% to 2.7% and 0.5% to 8.3% for accuracy and from 3.5% to 12% and 1.6% to 13.6% for precision, respectively. The mean recovery of BZ was greater than 91%. Partitioning ratios for DBSs/plasma ranged from 0.95 to 1.02. A cohort of 10 infants and six children with infection being treated with BZ had median BZ concentrations of 1.2 (IQR 0.29, 2.14) µg/mL with seven of 65 (11%) samples above the BZ treatment goal of 3 μg/mL for adults. The reported DBS assay is a simple and accurate method for the quantitative measurement of BZ that can be applied to facilitate urgently needed clinical studies of BZ for the treatment of Chagas disease and assess BZ adherence in resource-limited settings.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0852
2019-05-20
2020-09-19
Loading full text...

Full text loading...

/deliver/fulltext/14761645/101/1/tpmd180852.html?itemId=/content/journals/10.4269/ajtmh.18-0852&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2016. Chagas Disease (American Trypano-Somiasis). Geneva, Switzerland: WHO.
    [Google Scholar]
  2. Schmunis GA, 2007. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 102 (Suppl 1): 7585.
    [Google Scholar]
  3. Schmunis GA, Yadon ZE, 2010. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 115: 1421.
    [Google Scholar]
  4. Yadon ZE, Schmunis GA, 2009. Congenital Chagas disease: estimating the potential risk in the United States. Am J Trop Med Hyg 81: 927933.
    [Google Scholar]
  5. Buekens P, Almendares O, Carlier Y, Dumonteil E, Eberhard M, Gamboa-Leon R, James M, Padilla N, Wesson D, Xiong X, 2008. Mother-to-child transmission of Chagas’ disease in North America: why don’t we do more? Matern Child Health J 12: 283286.
    [Google Scholar]
  6. Kratz JM, Garcia Bournissen F, Forsyth CJ, Sosa-Estani S, 2018. Clinical and pharmacological profile of benznidazole for treatment of Chagas disease. Expert Rev Clin Pharmacol 11: 943957.
    [Google Scholar]
  7. Bermudez J, Davies C, Simonazzi A, Pablo Real J, Palma S, 2016. Current drug therapy and pharmaceutical challenges for Chagas disease. Acta Trop 156: 116.
    [Google Scholar]
  8. Bern C, 2011. Antitrypanosomal therapy for chronic Chagas’ disease. N Engl J Med 364: 25272534.
    [Google Scholar]
  9. Maya JD, Cassels BK, Iturriaga-Vásquez P, Ferreira J, Faúndez M, Galanti N, Ferreira A, Morello A, 2007. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol 146: 601620.
    [Google Scholar]
  10. Perez-Molina JA, Perez-Ayala A, Moreno S, Fernandez-Gonzalez MC, Zamora J, Lopez-Velez R, 2009. Use of benznidazole to treat chronic Chagas’ disease: a systematic review with a meta-analysis. J Antimicrob Chemother 64: 11391147.
    [Google Scholar]
  11. Morillo CA et al., 2015. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med 373: 12951306.
    [Google Scholar]
  12. Pecoul B et al., 2016. The BENEFIT trial: where do we go from here? PLoS Negl Trop Dis 10: e0004343.
    [Google Scholar]
  13. Altcheh J, Moscatelli G, Mastrantonio G, Moroni S, Giglio N, Marson ME, Ballering G, Bisio M, Koren G, Garcia-Bournissen F, 2014. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS Negl Trop Dis 8: e2907.
    [Google Scholar]
  14. Soy D, Aldasoro E, Guerrero L, Posada E, Serret N, Mejia T, Urbina JA, Gascon J, 2015. Population pharmacokinetics of benznidazole in adult patients with Chagas disease. Antimicrob Agents Chemother 59: 33423349.
    [Google Scholar]
  15. Molina I, Salvador F, Sanchez-Montalva A, Artaza MA, Moreno R, Perin L, Esquisabel A, Pinto L, Pedraz JL, 2017. Pharmacokinetics of benznidazole in healthy volunteers and implications in future clinical trials. Antimicrob Agents Chemother 61: e01912e01916.
    [Google Scholar]
  16. Wiens MO, Kanters S, Mills E, Peregrina Lucano AA, Gold S, Ayers D, Ferrero L, Krolewiecki A, 2016. Systematic review and meta-analysis of the pharmacokinetics of benznidazole in the treatment of Chagas disease. Antimicrob Agents Chemother 60: 70357042.
    [Google Scholar]
  17. Thomas A, Deglon J, Steimer T, Mangin P, Daali Y, Staub C, 2010. On-line desorption of dried blood spots coupled to hydrophilic interaction/reversed-phase LC/MS/MS system for the simultaneous analysis of drugs and their polar metabolites. J Sep Sci 33: 873879.
    [Google Scholar]
  18. Knudsen R, Slazyk W, Richmond J, Hannon W, 1995. Guidelines for the Shipment of Dried Blood Spot Specimens. Centers for Disease Control and Prevention Office of Health and Safety Biosafety Branch. 9(1).
  19. Spooner N, Lad R, Barfield M, 2009. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal Chem 81: 15571563.
    [Google Scholar]
  20. Soares-Sobrinho JL, de La Roca Soares MF, Lopes PQ, Correia LP, de Souza FS, Macêdo RO, Rolim-Neto PJ, 2010. A preformulation study of a new medicine for Chagas disease treatment: physicochemical characterization, thermal stability, and compatibility of benznidazole. AAPS PharmSciTech 11: 13911396.
    [Google Scholar]
  21. Buekens P et al., 2013. Congenital transmission of Trypanosoma cruzi in Argentina, Honduras, and Mexico: study protocol. Reprod Health 10: 55.
    [Google Scholar]
  22. Buekens P et al., For The Congenital Chagas Working Group, 2018. Congenital transmission of Trypanosoma cruzi in Argentina, Honduras, and Mexico: an observational prospective study. Am J Trop Med Hyg 98: 478485.
    [Google Scholar]
  23. Altcheh J et al., 2014. Population Pharmacokinetics Study of Benznidazole in Children with Chagas Disease. 17th World Congress of Basic and Clinical Pharmacology, Cape Town, South Africa, July 3–18, 2014.
  24. Matuszewski BK, Constanzer ML, Chavez-Eng CM, 2003. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC−MS/MS. Anal Chem 75: 30193030.
    [Google Scholar]
  25. Raaflaub J, 1980. Multiple-dose kinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung 30: 21922194.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0852
Loading
/content/journals/10.4269/ajtmh.18-0852
Loading

Data & Media loading...

  • Received : 23 Oct 2018
  • Accepted : 02 Apr 2019
  • Published online : 20 May 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error